AI Article Synopsis
- This study examines discrepancies in total IgE reference intervals (RIs) used by Scandinavian and British laboratories compared to those suggested by recent studies.
- Data from 122 of 172 accredited laboratories showed that 89% reported adult upper limits of 81 to 150 kU/L, with Denmark and Sweden having the most consistent RIs.
- The findings indicate that many laboratories may rely on outdated RIs, as published studies suggest significantly higher upper limits, highlighting a need for labs to reassess and update their reference intervals.
Article Abstract
Objectives: There appears to be marked discrepancies between total IgE reference intervals (RIs) in use by many laboratories and those recommended by published studies. The aim of this study was therefore to review total IgE RIs currently reported by Scandinavian and British laboratories and to compare these to published RIs identified by a literature review.
Methods: Relevant laboratories were identified by test directories provided by the national accreditation bodies in Norway, Sweden, Denmark and the UK. Total IgE RIs and their sources were acquired by accessing laboratory user handbooks or by an electronic survey. In addition a literature review of published total IgE RI studies was performed.
Results: From 172 accredited laboratories providing total IgE analysis, data was acquired from 122 laboratories. An adult upper reference limit between 81 to 150 kU/L was reported by 89% of these. Denmark and Sweden reported the most harmonised RIs whilst Norway and the UK exhibited the least degree of harmonisation. Published adult ( = 6) and paediatric ( = 6) RI studies reported markedly higher upper limits than those currently in use by the laboratories included in this study. There were also large variations in the number of age strata in use for paediatric RIs.
Conclusion: This study demonstrates large variations in currently utilised IgE RIs by Scandinavian and British accredited laboratories and most report markedly lower RIs than those recommended by recent RI publications. Many laboratories likely utilise outdated RIs and should consider critically reviewing and updating their RIs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/00365513.2023.2261102 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of LPCAT1-rs8352 genetic variant with susceptibility and severity of pediatric bronchial asthma: a case-control study.
BMC Pediatr
January 2025
Department of Pediatrics, Faculty of Medicine, Assiut University, Egypt, 71515, Assiut, Egypt.
Background: This study aimed to investigate the possible association of LPCAT1-rs8352 genetic variant (single nucleotide change C to G) with the onset and severity of pediatric asthma. Additionally, the study examined the influence of LPCAT1-rs8352 genotypes on asthma-related biomarkers including blood eosinophils count (BEC), eosinophil cationic protein (ECP), high-sensitivity C-reactive protein (hs-CRP), and immunoglobulin E (IgE) and on lung function [forced expiratory volume in one second (FEV1) and the forced vital capacity (FVC)].
Patients And Methods: The study included ninety-six participant grouped into two groups: G1 (46 asthmatics) and G2 (50 healthy controls).
An IgM Cleaving Enzyme for Clearance of Anti-Pig Xenoreactive Antibodies in a Nonhuman Primate Model.
Xenotransplantation
January 2025
Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
Background: The removal of preformed antibodies with cleaving enzyme like IdeS (Imlifidase) has demonstrated therapeutic potential in organ transplantation for sensitized recipients. However, preformed xenoreactive antibodies (XAbs) against porcine glycans are predominantly IgM and considered detrimental in pig-to-human xenotransplantation.
Methods: Recombinant IceM, an endopeptidase cleaving IgM, was generated in Escherichia coli.
Changes in and Potential Mechanisms of Circulating IgA+CD27-Class-Switched Memory B Cells in Patients With Allergic Rhinitis.
J Asthma Allergy
January 2025
Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China.
Background: The role of memory B cells and their subgroups in allergic rhinitis (AR) and allergen immunotherapy (AIT) remains unclear. This study aimed to investigate the characteristics of memory B cells in the circulation of patients with AR and those undergoing AIT, as well as their clinical significance.
Methods: This study involved a cohort comprising 32 healthy control subjects, 39 individuals diagnosed with AR, and 31 AR patients who had received AIT for over one year.
A nomogram for predicting bladder dysfunction in patients with type 2 diabetes mellitus: a retrospective study.
PeerJ
January 2025
Department of Nursing, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Background: Diabetic bladder dysfunction (DBD) is a common urinary complication in diabetic patients, significantly affecting their overall well-being and quality of life, and placing a considerable burden on healthcare resources. Early prevention is crucial; however, the absence of a simple and effective tool to predict DBD onset remains a significant challenge. This study aims to identify risk factors for DBD in patients with type 2 diabetes mellitus (T2DM) and to develop a predictive nomogram for clinical application.
View Article and Find Full Text PDFEffectiveness of Tralokinumab in Different Phenotypes of Atopic Dermatitis: A Real-World Study.
Dermatol Ther (Heidelb)
January 2025
Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", "Sapienza" University of Rome, Polo Pontino, 04100, Latina, Italy.
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and a relapsing course, affecting approximately 25% of children and 4-7% of adults. This study evaluated the efficacy, safety, and quality-of-life impact of tralokinumab, a humanized monoclonal antibody targeting interleukin-13 (IL-13), in treating moderate-to-severe AD in a real-world setting, with a focus on different AD phenotypes.
Methods: An observational cohort of 30 adults treated with tralokinumab for ≥ 16 weeks was analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!